Gout significantly affects patients with advanced CKD
Click Here to Manage Email Alerts
For patients with advanced chronic kidney disease, gout can significantly increase health care utilization and comorbidities, according to a study presented at ASN Kidney Week.
The study, presented by Leonard Stern, MD, a nephrologist at Columbia University Irving Medical Center in New York, found patients with CKD and uncontrolled gout faced increased health burdens, increased colchicine use and poorer toxicity profiles.
"Among CKD patients, gout is common, impactful and requires careful screening and collaborative management," Stern and colleagues wrote.
A total of 111 nephrologists provided chart data on patients with stage 3-5 CKD.
Of the 746 patients, 173 had gout. Patients with gout were further categorized having either controlled or uncontrolled gout. Overall, 13% had uncontrolled gout. Investigators compared results of patients with gout, patients with uncontrolled gout and patients without gout.
The comparison demonstrated patients with advanced CKD and gout more often required medical care and presented with symptoms, such as urination changes and shortness of breath, compared with patients without gout. Patients with gout also showed a greater rate of CKD-mineral bone disorder, ischemic heart disease, congestive heart failure, peripheral vascular disease and chronic pain.
In a comparison of patients with controlled gout vs. patients with uncontrolled gout, investigators found pulmonary hypertension, joint issues, chronic pain, febuxostat use and colchicine use were more common in patients with uncontrolled gout.
Collapse
Stern L, et al. Abstract PUB316. Presented at: ASN Kidney Week; Nov. 2-7, 2021 (virtual meeting).
Click Here to Manage Email Alerts